175 related articles for article (PubMed ID: 8450906)
1. Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin.
Romero R; Novoa D; Otero S; Alonso MC; Alonso R; Arcocha V; Arza D; Lens XM; Sanchez-Guisande D
Nephron; 1993; 63(2):164-7. PubMed ID: 8450906
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
Tarng DC; Huang TP
Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432
[TBL] [Abstract][Full Text] [Related]
3. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
Casati S; Castelnovo C; Campise M; Ponticelli C
Nephrol Dial Transplant; 1990; 5(6):441-3. PubMed ID: 2122321
[TBL] [Abstract][Full Text] [Related]
4. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
[TBL] [Abstract][Full Text] [Related]
5. Effect of body iron stores on serum aluminum level in hemodialysis patients.
Huang JY; Huang CC; Lim PS; Wu MS; Leu ML
Nephron; 1992; 61(2):158-62. PubMed ID: 1630539
[TBL] [Abstract][Full Text] [Related]
6. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
[TBL] [Abstract][Full Text] [Related]
7. Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients.
Aucella F; Vigilante M; Scalzulli P; Musto P; Crisetti A; Modoni S; Carotenuto M; Stallone C
Nephrol Dial Transplant; 1998 May; 13(5):1194-9. PubMed ID: 9623553
[TBL] [Abstract][Full Text] [Related]
8. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
10. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
11. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
[TBL] [Abstract][Full Text] [Related]
12. Red cell ferritin, a marker of iron deficiency in hemodialysis patients.
Bhandari S; Owda AK; Kendall RG; Moran N; Norfolk DR; Brownjohn AM; Turney JH
Ren Fail; 1997 Nov; 19(6):771-80. PubMed ID: 9415934
[TBL] [Abstract][Full Text] [Related]
13. Serum transferrin receptor concentration is not indicative of erythropoietic activity in chronic hemodialysis patients with poor response to recombinant human erythropoietin.
Hou CC; Wu SC; Wu SC; Yang WC; Huang TP; Ng YY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Aug; 61(8):456-62. PubMed ID: 9745161
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
[TBL] [Abstract][Full Text] [Related]
15. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH; Chang CC; Chiang SS
Clin Nephrol; 2002 Feb; 57(2):136-41. PubMed ID: 11863124
[TBL] [Abstract][Full Text] [Related]
16. The target hemoglobin content values of reticulocytes for efficient anemia improvement are achieved by low ferritin levels and moderate transferrin saturation: a retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Shimada K; Kanda F; Maeda K
Hematology; 2020 Dec; 25(1):71-78. PubMed ID: 32009585
[No Abstract] [Full Text] [Related]
17. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
18. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
19. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of intestinal iron absorption by indirect methods in patients on hemodialysis receiving oral iron and recombinant human erythropoietin.
Deira J; Martín M; Sánchez S; Garrido J; Núñez J; Tabernero JM
Am J Kidney Dis; 2002 Mar; 39(3):594-9. PubMed ID: 11877579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
